More new agents than available patients to test them?

[Guest guest]

PAL analysis:

<http://www.lymphomation.org/lymphoma-enrollment.pdf> Lymphoma

<http://www.lymphomation.org/lymphoma-enrollment.pdf> - trials and

prevalence vs. breast cancer http://bit.ly/qb0Kak

The number of lymphoma studies is about equivalent to breast cancer (2,272

versus 2,112, respectively) despite the

much lower prevalence of lymphoma (417,860 versus 2,605,181).

This imbalance suggests an optimism among drug sponsors about the potential

to more effectively treat lymphoma, because prevalence would otherwise favor

more breast cancer research, assuming marketing potential is a key factor.

However, the relatively low number of patients per study increases the

challenge to enroll sufficient participants -- 24 participants available per

study for lymphoma, versus 150 for breast cancer.

Action: The enrollment rate must increase significantly if we are to make

good on the insights into the biology of lymphoma

which are waiting to be exploited.

All the best,

~ Karl

Patients Against Lymphoma

Patients Helping Patients

Non-profit | Independent | Evidence-based

www.lymphomation.org | Current News: http://bit.ly/f2A0T

How to Help: www.lymphomation.org/how-to-help.htm